> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Coastlands Holds 5.34% Of ALX Oncology Through Its Investment Partnership
- URL: https://www.bullished.co/coastlands-holds-5-34-of-alx-oncology-through-its-investment-partnership-339dc60c/
- Published: 2026-11-20T00:11:10.000Z
- Updated: 2026-11-20T00:11:10.000Z
- Description: The passive position covers 6,906,783 shares as the cancer-drug developer prepares for an expected December trial update.
- Author: Matteo Parrino
- Tags: SEC Filings, ALXO, Industry: Healthcare

Coastlands Capital, an investment adviser, reported Thursday a [5.34% passive stake](https://www.sec.gov/Archives/edgar/data/0002068530/000110465926130295/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [ALX Oncology](https://www.bullished.co/tag/alxo/), which develops cancer therapies, in an SEC ownership disclosure. The position covers 6,906,783 common shares held directly by Coastlands Capital Partners as of November 12.

## The Partnership Holds The Shares

Coastlands Capital Partners holds the stock for its investors and can receive or direct dividends and proceeds from share sales. Coastlands Capital serves as the partnership's investment adviser.

Matthew D. Perry, the control person of the Coastlands entities, reported shared voting authority over the same shares. The partnership, its adviser, the related Coastlands entities and Perry each reported the same position; those entries describe the shares held by the partnership.

The reported percentage uses 129,274,568 common shares outstanding as of November 9\. Coastlands certified that the securities were bought and are held without an aim or effect of influencing ALX's control.

## Cancer Trials And $147.2 Million

ALX reported [$147.2 million](https://www.globenewswire.com/news-release/2026/11/16/3403470/0/en/alx-oncology-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html?ref=bullished.co) in cash, cash equivalents and investments at September 30\. Management expects those resources to fund planned operations through the first half of 2028.

The company has no approved products for sale. Its candidates include evorpacept, which blocks CD47—a protein that helps cancer cells evade immune attacks—and ALX2004, an antibody-drug conjugate targeting EGFR, a protein on some tumors.

Evorpacept's development includes a mid-stage study in metastatic HER2-positive breast cancer. In September, ALX announced published gastric-cancer trial findings showing higher response rates than the control treatment, supporting further development of the drug.

Jazz Pharmaceuticals and Sanofi sponsor studies pairing evorpacept with their own medicines. ALX's annual-report profile said approximately 800 subjects had received evorpacept alongside other cancer treatments.

## ALX2004's December Readout

ALX2004 entered an early-stage trial in August 2025\. ALX expects [safety and early](https://www.globenewswire.com/news-release/2026/11/16/3403470/0/en/alx-oncology-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html?ref=bullished.co) efficacy findings in December 2026 from that study in patients with selected advanced or metastatic solid tumors.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Coastlands Capital LP re: ALX Oncology Holdings Inc. (ALXO)](https://www.sec.gov/Archives/edgar/data/0002068530/000110465926130295/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99.1 — EXHIBIT 99.1](https://www.sec.gov/Archives/edgar/data/2068530/000110465926130295/tm2630323d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [ALX Oncology Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/16/3403470/0/en/alx-oncology-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html?ref=bullished.co) — globenewswire.com

### More on ALX Oncology Holdings

- [ALX Oncology Stock Plunges 11% After Earnings — Its Quarterly Loss Narrows](https://www.bullished.co/alx-oncology-stock-plunges-11-after-earnings-its-quarterly-loss-narrows-76d079f2/)
- [ALX Oncology's $147.2 Million Cash Pool Is Expected To Fund Operations Into 2028](https://www.bullished.co/alx-oncologys-147-2-million-cash-pool-is-expected-to-fund-operations-into-2028-f9ffd917/)
- [venBio Fund Trades 253,826 ALX Oncology Shares For A Pre-Funded Warrant, Goodman Filing Shows](https://www.bullished.co/venbio-fund-trades-253-826-alx-oncology-shares-for-a-pre-funded-warrant-goodman-filing-56b5db7b/)

[All ALX Oncology Holdings (ALXO) coverage →](https://www.bullished.co/tag/alxo/)